It is administered to Rh-negative mothers who are not already allo-immunized to anti-D and who have potential exposure to Rh-positive red blood cells (RBCs).
Administration is via intramuscular injection using a pre-measured 1 ml syringe with an attached needle.
Dosing
There are two main doses: micro dose and full dose.
Micro Dose RhIG
Indications:
After abortion, miscarriage, or termination of ectopic pregnancy.
Administration should occur at 12 weeks gestation (antepartum).
Dosage:
Micro dose = 50 \mu g of anti-D.
Protects against 2.5 ml of Rh+ RBCs or 5 ml of Rh+ whole blood (WB).
Full Dose RhIG
Indications:
After amniocentesis/cordocentesis.
Following abdominal trauma during pregnancy.
Antepartum hemorrhage.
Postpartum.
Administration:
Following an abortion or miscarriage after 12 weeks gestation.
At ≥ 28 weeks gestation (antepartum).
Within 72 hours postpartum:
When the infant is Rh-positive or the fetal Rh is unknown (e.g., fetal demise/stillborn, miscarriage, etc.).
When the mother has not developed an allo-anti-D.
Dosage:
Full dose = 300 \mu g of anti-D.
Protects against 15 ml of Rh+ RBCs or 30 ml of Rh+ WB.
Antepartum Injection of RhIG
If a mother receives an antepartum RhIG injection, a weak AHG reaction may be detected in the antibody screen (ABS).
The antibody identification panel will reveal a weak reacting anti-D.
After verifying the patient's chart for evidence of antepartum RhIG administration, this anti-D Ab is reported as "passive anti-D," not "allo" anti-D.
Calculation for RhIG Dosage
Formula: Fetal cells volume (from Kleihauer-Betke (KB) test result) / 30 = # of syringes to be given.
When calculating the number of RhIG vials, include one decimal place (X.X).
Rounding:
If the decimal is < 0.5, round down (e.g., 2.2 = 2).
If the decimal is ≥ 0.5, round up (e.g., 2.7 = 3).
Always add 1 to the calculated dose to ensure an adequate dose (e.g., calculated dose is 2 + 1 = 3; calculated dose is 3 + 1 = 4).
Rh Factor Sensitization Prevention
Rh-negative mothers who have not been previously sensitized to the Rh factor receive an intramuscular injection of Rhesus Immune Globulin to prevent antibody formation.
The injection is administered at 28 weeks of pregnancy and within 72 hours of the birth of a confirmed Rh-positive baby.
Sensitivity to blood titers is checked 6 months after the last Rhogam injection following the birth of an Rh-positive baby to rule out false positives.
If titers remain positive after 6 months, sensitization has occurred.
Other Treatments: IV RhIG
Following accidental transfusion with Rh+ RBCs into an Rh-negative recipient.
Intramuscular injection is not the appropriate therapy when the blood volume is larger than 30 ml. Use IV Rh Immune Globulin, e.g., WinRho@.
The blood bank (BB) can calculate the amount to be given based on the quantity of Rh+ RBCs transfused.
Consult the BB Medical Director.
Immune Thrombocytopenia Purpura (ITP)
Treatment of ITP:
The BB does not issue IV Rh Immune Globulin for ITP treatment; this may be a pharmacy intervention.
ITP is a blood disorder caused by a low platelet count, resulting in petechiae.
RhIG elevates the platelet count in these patients.
Anti-D Immune Globulin can be used as a substitute for IVIg for maintenance therapy, especially in patients with contraindications to splenectomy.
Coats red cells with IgG and allows red cells to serve as a decoy for splenic macrophages.
Patient must be Rh-positive.
Not effective after splenectomy.
Designed to cause hemolytic anemia; hemoglobin may drop as much as 3g/dl.
Intermittent dosing may allow patients to avoid splenectomy.